In contrast to breast cancer, basolateral HER2 staining in immunohistochemistry (IHC) is considered HER2 + because incomplete membranous staining is common in GC (Hofmann et al. 2008; Rüschoff et al. 2012). This evidence concerns the gene ERBB2 and breast carcinoma.